ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1867

Profiling Cytokine Production Of B Cells From SLE Patients Upon TLR9 Stimulation

Julia Sieber1, Capucine Daridon2, Simon Fillatreau3 and Thomas Dörner1, 1CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, 2Department of Medicine/Rheumatology and Clinical Immunology, Charité University Medicine / German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, 3German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: B cells, SLE and cytokines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Beyond their antibody producing function, B cells have been shown to be potent antigen-presenting and cytokine-producing cells. In systemic lupus erythematosus (SLE), B cells have been reported to be hyper-reactive, but it is not entirely known how cytokine production changes. An important signaling mechanism in B cell hyper-reactivity is Toll-like receptor 9 (TLR-9), which is up-regulated in B cells from patients with active SLE. Therefore, the aim of this study was to profile the cytokine production by B cells upon TLR-9 activation and to compare healthy donors (HD) to SLE-patients. In addition, the capacities of B cells to produce cytokines were put in relation with disease activity (SLEDAI) and serum autoantibody titers.

Methods: Untouched B cells from 19 SLE-patients and 13 HD were purified from peripheral blood mononuclear cells and were stimulated in vitro using CpG for 48 hours. The culture supernatants were harvested and then tested for 28 cytokines and chemokines by Bio-Plex. The cytokine responses upon stimulation were compared between both groups and correlated with the SLEDAI and anti-dsDNA titers for SLE-patients.

Results: 24 out of 28 cytokines/chemokines measured were significantly up-regulated upon TLR-9 stimulation compared to un-stimulated B cells (p<0.05). Although B cells from SLE patients showed a trend to produce less cytokine than B cells from HD, no significant differences were observed. However, the amount of IL-2, IL-4, IL-7, IL-12p70, IL13, IL-15, IL-17A, Eotaxin, Basic FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MIP-1α, and VEGF produced by B cells from SLE-patients inversely correlated with their SLEDAI (p<0.05) and even more (additionally IL-1β, IL-1ra, MIP-1β and TNF-α) with their anti-dsDNA antibody titers. Interestingly, the more CD27+ memory B cells were in the cells culture from SLE-patients, the more IP-10 and TNF-α were produced.

Conclusion: This study highlighted unknown perturbations of cytokine/chemokine production by B cells in active SLE upon TLR-9 stimulation with an inverse correlation of cytokines/chemokines produced by B cells with SLEDAI and anti-dsDNA titers. Most prominent were pro-inflammatory mediators as IP-10, MIP-1α, TNF-α, and VEGF. This suggests that the known enhanced B cell proliferation and differentiation upon TLR9-stimulation possibly results in a diminished cytokine production.


Disclosure:

J. Sieber,
None;

C. Daridon,
None;

S. Fillatreau,
None;

T. Dörner,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/profiling-cytokine-production-of-b-cells-from-sle-patients-upon-tlr9-stimulation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology